Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer intraday update reveals robust revenue growth, dividend strength and legal challenges shaping its strategic trajectory.
Pfizer strategically focuses on oncology via collaborations like Summit Therapeutics, navigating regulatory changes and new coronavirus variants. Legal challenges and vaccine demand present risks.
Pfizer focuses on oncology via collaborations, addresses coronavirus concerns, and faces a Depo-Provera probe. Cavazzoni's CMO role could streamline approvals, while value stocks gain traction.
Pfizer focuses on oncology with Ivonescimab, appoints Patrizia Cavazzoni as CMO, and navigates vaccine demand and legal challenges, maintaining investor appeal.
A comprehensive, data-driven update on Pfizer Inc.'s strategic pivot, pipeline realignment, legal investigations, and market challenges.
Pfizer navigates strategic shifts, ending gene therapy development while focusing on oncology amid legal scrutiny, impacting investor sentiment and future prospects.
A detailed data-driven update on Pfizer’s latest developments, clinical breakthroughs, and regulatory challenges affecting [PFE](/dashboard/companies/PFE).
A comprehensive intraday analysis of Pfizer covering legal scrutiny, breakthrough clinical trials, dividend yields, and strategic market responses.